SIGA - SIGA Technologies, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

SIGA Technologies, Inc.

31 East 62nd Street
New York, NY 10065
United States

Full Time Employees41

Key Executives

NameTitlePayExercisedYear Born
Dr. Eric A. RoseChairman620.14k2.2M1951
Dr. Phillip Louis Gomez IIICEO & Director1.54MN/A1967
Mr. Daniel J. LuckshireExec. VP, CFO & Sec.1.2M376.2k1971
Dr. Dennis E. HrubyVP & Chief Scientific Officer1.19M253.12k1952
Ms. Robin E. AbramsGen. Counsel & Chief Admin. Officer1.04MN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was founded in 1995 and is headquartered in New York, New York.

Corporate Governance

SIGA Technologies, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.